Bayer

This study compares two treatments for men with prostate cancer that has spread to bones and is no longer responding to hormone therapy. One group receives radium-223, a radioactive drug that targets bone tumors, while the other continues with standard oral hormone drugs. The goa…

This study looks at adults with hemophilia A who choose to take Jivi, a longer-lasting clotting factor, to prevent bleeding. Researchers will use ultrasound to check joint health after 24 months of treatment. The goal is to see if Jivi helps maintain or improve joint status in ev…

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer spread or death in men with high-risk biochemical recurrence of prostate cancer. About 985 men will receive either darolutamide plus ADT or a placebo plus ADT for up to 24 months. The …

This early-stage study tests a new drug called 225Ac-pelgi for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers a short-range radioactive payload directly to cancer cells, aiming to kill them while sparing nearby he…

This study monitors the safety and side effects of the drug sorafenib (Nexavar) in people with a type of advanced thyroid cancer that cannot be removed by surgery. Over 450 participants are being followed for up to 2 years to track side effects, how long they stay on treatment, a…

This study tests a new drug called aficamten in 36 Japanese adults with a heart condition that makes the heart muscle too thick, making it hard to pump blood. The drug works by relaxing the heart muscle to improve blood flow. Researchers will check if it reduces symptoms and impr…

This study watches 300 adults with advanced liver cancer that can't be removed by surgery. All have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine doctor visits to see how well different sec…

This study reviews existing health records from about 3000 people in Japan who received aflibercept 8 mg injections for two eye conditions that cause vision loss. Researchers will describe the patients' characteristics and how the drug was used over one year. No new treatments or…

This observational study tracks 75 Japanese babies with retinopathy of prematurity (ROP) who are already prescribed Eylea. Researchers will collect safety and effectiveness data from routine medical visits over 6 months. The goal is to see how well Eylea works and what side effec…

This study looks at medical records from over 600 Indian adults with chronic heart failure who were prescribed the drug vericiguat between 2022 and 2023. Researchers want to see how well the drug works and how safe it is in everyday medical practice. No new treatments or tests ar…

This study reviews medical records of 1,200 Indian adults with chronic kidney disease and type 2 diabetes who started taking finerenone between August 2022 and April 2024. Researchers will look at how doctors prescribed the drug, dose changes, and lab results like kidney function…

This study looks at real-world data from 150,000 people with chronic kidney disease and type 2 diabetes to see how safe and effective the drug finerenone is in routine medical care. Researchers will compare heart problems like heart attacks and hospitalizations for heart failure …

This study looks at how a new medicine for chronic kidney disease, nurandociguat, affects the way the body processes two other drugs (rosuvastatin and dabigatran). Healthy adults aged 18 to 58 will take these drugs alone and then with nurandociguat to measure drug levels and chec…